Memantine to Reduce Cognitive Impairment After Radiation in Children: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients after Radiation Therapy for Central Nervous System Tumors
International Journal of Radiation Oncology*Biology*Physics · 2024
DOI: 10.1016/j.ijrobp.2024.05.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Elizabeth L McKone und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Memantine, Feasibility Studies, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Mayo Clinic.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE: Memantine is standard in certain adults receiving brain radiation therapy (RT) to decrease cognitive impacts, but it is unknown whether pediatric patients can take, tolerate, and/or benefit from memantine. In this prospective single-arm feasibility study, we hypothesized that pediatric patients receiving central nervous system (CNS) RT would tolerate memantine with good adherence. METHODS AND MATERIALS: Patients aged 4 to 18 years with a primary CNS malignancy (excluding World Health Organization grade 4 astrocytoma, glioblastoma) receiving intracranial RT were eligible. A 6-month memantine course was given during and after RT, with dose titration in 5 mg increments over 4 weeks targeting a weight-based maximum (0.4 mg/kg to the closest 5 mg), not to exceed 10 mg twice a day. The primary endpoint was to achieve 80% drug adherence rate in 80% of patients measured 1 month after RT. Secondary objectives included memantine feasibility at 3 and 6 months. RESULTS: Eighteen patients enrolled from 2020 to 2022 and were prescribed memantine with RT. The study closed early to avoid competing with the phase 3 randomized Children's Oncology Group study ACCL2031. No predefined stopping rules were met. One patient withdrew for cognition-altering substance use, leaving 17 patients available for analysis. One patient discontinued memantine after one dose due to nausea. For the remaining 16 patients, there was a median of 100% pill completion rate (range, 74%-100%; n = 9/17 with 100% adherence) at 1 month after RT, with 15/16 (94%) with adherence rates >80%. At the 3- and 6-month post-RT time points for secondary endpoints, the median adherence rates were 100% (range, 55%-100%) and 96% (range, 33%-100%), respectively. Grade 1 to 2 fatigue, headache, and nausea were the most common toxicity events, at least possibly related to the study drug (n = 27), without attributable grade 3+ events. CONCLUSIONS: Memantine is a feasible, safe, and well-tolerated addition to multimodality treatment for pediatric CNS malignancies. Results of ACCL2031 are awaited to define the value of memantine in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.
- Department of Qualitative Health Sciences, Section of Biostatistics, Mayo Clinic, Scottsdale, Arizona.
- Department of Neonatology, Seattle Children's Hospital, Seattle, Washington.
- Department of Pediatric Hematology/Oncology, Section of Neuro-Oncology, Mayo Clinic, Rochester, Minnesota.
- Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
Förderung
- Mayo Clinic
Zitieren
APA
McKone, E. L., Breen, W. G., Foster, N. R., Bogan, A. W., Connors, M. A., Alstat, R. A., Schwartz, J. D., Mahajan, A., Ahmed, S. K., & Laack, N. N. (2024). Memantine to Reduce Cognitive Impairment After Radiation in Children: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients after Radiation Therapy for Central Nervous System Tumors. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.05.031
Vancouver
McKone EL, Breen WG, Foster NR, Bogan AW, Connors MA, Alstat RA, et al. Memantine to Reduce Cognitive Impairment After Radiation in Children: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients after Radiation Therapy for Central Nervous System Tumors. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.05.031
BibTeX
@article{McKone2024,
author = {McKone, Elizabeth L and Breen, William G and Foster, Nathan R and Bogan, Aaron W and Connors, Margaret A and Alstat, Reece A and Schwartz, Jonathan D and Mahajan, Anita and Ahmed, Safia K and Laack, Nadia N},
title = {Memantine to Reduce Cognitive Impairment After Radiation in Children: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients after Radiation Therapy for Central Nervous System Tumors},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
doi = {10.1016/j.ijrobp.2024.05.031}
}
EUVIMED